Joshua Ruch, an insider at GeneDx Holdings Corp (WGS), sold 24,390 shares of the company on November 23, 2025, at a price of $161.16 per share. This transaction totaled approximately $3.93 million. Following the sale, Ruch retains an equal number of shares in the company.
GeneDx Holdings Corp operates as a health intelligence company based in Stamford, Connecticut, employing around 1,000 full-time staff. The firm focuses on exome and genome testing through its subsidiary, GeneDx, LLC, which aims to translate complex genomic data into actionable health insights. Its service offerings include a range of pediatric and rare disease diagnostics, primarily through whole exome and genome sequencing.
The company, which went public on September 4, 2020, has a market capitalization of $4.0 billion. As of November 18, 2025, GeneDx reported a price-to-earnings ratio of 1,922.81 and an earnings per share of 0.06. Upcoming earnings are expected on July 27, 2026, with an estimated EPS of $0.04 and revenue of $125.7 million.
Insider transactions such as Ruch's are reported to the SEC, providing transparency regarding executive stock ownership. While such sales may raise questions, they do not necessarily indicate a negative outlook for the company. Investors are encouraged to consider broader patterns of insider activity rather than isolated transactions when assessing these signals.